Spray to prevent flu FDA approves AstraZeneca's FluMist vaccine
Market VisionFriday, Sep 20, 2024 8:00 pm ET
1min readThe U.S. FDA approved AstraZeneca's (AZN.US) FluMist, a nasal spray vaccine, for the prevention of influenza disease caused by A and B influenza viruses in people aged 2 to 49. FluMist is the first influenza vaccine available for eligible patients to self-administer or for caregivers to administer.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet